Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Blincyto and Marqibo in R/R Ph- CD19+ ALL
NCT04448834Phase 2Withdrawn
- Start
- Jan 2022
- Primary completion
- Jun 2023
- Modality
- Antibody Conjugates, scFv Fragments, Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of blinatumomab, vincristine in acute lymphoblastic leukemia (ALL). Planned start Jan 2022; status: withdrawn.
02
Drugs
blinatumomabvincristine
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT04448834.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04448834.